Our small-molecule programme, led by S-pindolol benzoate (ACM-001.1), consists of multi-action agents that affect more than one pathway critical to the development of cachexia. It focuses on a class of agents that have multiple pharmalogical effects that result in:

•  A decrease in metabolism and the expenditure of energy

•  A reduction in breakdown of muscle and increased muscle growth

•  Increased appetite

Ultimately, this treatment method has the potential to improve patient quality of life and overall rates of survival.